IMMP
IMMUTEP Ltd
NASDAQ · Healthcare · Biotechnology · AU
$3.33
+0.30%Sep 30, 2026, 12:00 UTC
Immutep Limited received an A$856,669 cash rebate from the Australian Federal Government's R&D tax incentive program for eligible R&D expenditure incurred in the 2025 fiscal year.
Source:Sep 11, 2026, 01:54 UTC
Immutep outlined a refocused development strategy for eftilagimod alfa (efti), concentrating future registration-directed work on head and neck squamous cell carcinoma (CPS below 1) and neoadjuvant soft tissue sarcoma, following a root cause analysis of the discontinued TACTI-004 study.
Source:Jun 1, 2026, 15:58 UTC
A securities class action has been filed against Immutep Limited alleging violations of federal securities laws.